MX2024005740A - Anticuerpos sirp gamma y usos de estos. - Google Patents

Anticuerpos sirp gamma y usos de estos.

Info

Publication number
MX2024005740A
MX2024005740A MX2024005740A MX2024005740A MX2024005740A MX 2024005740 A MX2024005740 A MX 2024005740A MX 2024005740 A MX2024005740 A MX 2024005740A MX 2024005740 A MX2024005740 A MX 2024005740A MX 2024005740 A MX2024005740 A MX 2024005740A
Authority
MX
Mexico
Prior art keywords
antibodies
cells
useful
tnfî
methods
Prior art date
Application number
MX2024005740A
Other languages
English (en)
Spanish (es)
Inventor
Sandip Panicker
Adam David Rosenthal
Eileen Lingshu Rose
Allen Guo Yang Cai
Original Assignee
Electra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electra Therapeutics Inc filed Critical Electra Therapeutics Inc
Publication of MX2024005740A publication Critical patent/MX2024005740A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2024005740A 2021-11-10 2022-11-10 Anticuerpos sirp gamma y usos de estos. MX2024005740A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163277966P 2021-11-10 2021-11-10
PCT/US2022/079668 WO2023086906A2 (en) 2021-11-10 2022-11-10 Sirp gamma antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2024005740A true MX2024005740A (es) 2024-08-06

Family

ID=84488592

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005740A MX2024005740A (es) 2021-11-10 2022-11-10 Anticuerpos sirp gamma y usos de estos.

Country Status (11)

Country Link
US (1) US20240400677A1 (https=)
EP (1) EP4429768A2 (https=)
JP (1) JP2024543385A (https=)
KR (1) KR20240099454A (https=)
CN (1) CN118591556A (https=)
AU (1) AU2022386652A1 (https=)
CA (1) CA3237787A1 (https=)
IL (1) IL312776A (https=)
MX (1) MX2024005740A (https=)
TW (1) TW202334224A (https=)
WO (1) WO2023086906A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用
WO2025226685A1 (en) * 2024-04-22 2025-10-30 Electra Therapeutics, Inc. Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
JP7179743B2 (ja) * 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗ＳＩＲＰｇ抗体の新規の使用
JP7763666B2 (ja) * 2019-06-24 2025-11-04 アムジェン インコーポレイテッド 癌治療のためのＳＩＲＰγの阻害

Also Published As

Publication number Publication date
TW202334224A (zh) 2023-09-01
US20240400677A1 (en) 2024-12-05
KR20240099454A (ko) 2024-06-28
JP2024543385A (ja) 2024-11-21
CA3237787A1 (en) 2023-05-19
AU2022386652A1 (en) 2024-06-06
WO2023086906A3 (en) 2023-06-22
WO2023086906A2 (en) 2023-05-19
EP4429768A2 (en) 2024-09-18
IL312776A (en) 2024-07-01
CN118591556A (zh) 2024-09-03

Similar Documents

Publication Publication Date Title
MX2022009947A (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
MY205933A (en) Sirp-alpha binding proteins and methods of use thereof
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP4249067A3 (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use
MY208785A (en) Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2018237148A8 (en) Multispecific antibodies that target hiv gp120 and cd3
EA202190468A1 (ru) Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
MX2024005740A (es) Anticuerpos sirp gamma y usos de estos.
MX343747B (es) Agentes de union diana contra b7-h1.
MX2023014389A (es) Anticuerpos anti-sirp-alfa.
MX2023014645A (es) Proteinas acopladoras de celulas nk de union a nkp46 especificas de cd20.
MX2021014966A (es) Anticuerpos anti-cd3 dependientes de ph modificados geneticamente y metodos para su generacion y uso.
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
MX2023008000A (es) Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos.
EP4670724A3 (en) Anti-gprc5d monoclonal antibodies and uses thereof
PH12022551597A1 (en) ANTI-SIRPa MONOCLONAL ANTIBODIES AND USES THEREOF
MY202157A (en) Anti-pd-l1 antibody and use thereof
PH12023500005A1 (en) Multi-specific antigen binding molecules targeting hiv and methods of use
WO2020168231A3 (en) Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
WO2020014327A3 (en) Antibodies binding to vista at acidic ph
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
MX2022015948A (es) Proteínas de unión anti-ctla-4 y métodos de uso de estas.
WO2022232044A3 (en) Anti-clec12a antibodies and uses thereof
WO2022170008A3 (en) Anti-il1rap antibodies
MX2023001937A (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.